3-([1,1′-biphenyl]-4-yl)propanoyl chloride | 169894-52-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-([1,1′-biphenyl]-4-yl)propanoyl chloride
• 英文别名: 3-(Biphenyl-4-yl)propanoyl chloride；3-(4-phenylphenyl)propanoyl chloride
• CAS: 169894-52-4
• 化学式: C₁₅H₁₃ClO
• 分子量: 244.721
• InChiKey: AUSPKFNAXZHVDL-UHFFFAOYSA-N

物化性质

• 沸点：
  375.4±31.0 °C(Predicted)
• 密度：
  1.151±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.4
• 重原子数：
  17
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.13
• 拓扑面积：
  17.1
• 氢给体数：
  0
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-([1,1′-biphenyl]-4-yl)propanoyl chloride 在 三氯化铝 作用下， 以 二氯甲烷 为溶剂， 生成 6-phenylindan-1-one
  参考文献：
  名称：

  The discovery and synthesis of novel adenosine receptor (A2A) antagonists

  摘要：

  In high throughput screening of our file compounds, a novel structure 1 was identified as a potent A(2A) receptor antagonist with no selectivity over the A(1) adenosine receptor. The structure-activity relationship investigation using 1 as a template lead to identification of a novel class of compounds as potent and selective antagonists of A(2A) adenosine receptor. Compound 26 was identified to be the most potent A(2A) receptor antagonist (K-i = 0.8 nM) with 100-fold selectivity over the A(1) adenosine receptor. (c) 2005 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2005.01.019
• 作为产物：
  描述：

  ethyl (E)-3-([1,1'-biphenyl]-4-yl)acrylate 在 palladium on activated charcoal sodium hydroxide 、 草酰氯 、 氢气 作用下， 以 四氢呋喃 、 甲醇 、 乙醇 为溶剂， 反应 20.0h， 生成 3-([1,1′-biphenyl]-4-yl)propanoyl chloride
  参考文献：
  名称：

  Structure−Activity Relationships of α-Ketooxazole Inhibitors of Fatty Acid Amide Hydrolase

  摘要：

  A systematic study of the structure-activity relationships of 2b (OL-135), a potent inhibitor of fatty acid amide hydrolase (FAAH), is detailed targeting the C2 acyl side chain. A series of aryl replacements or substituents for the terminal phenyl group provided effective inhibitors (e.g., 5c, aryl = 1- napthyl, K-i = 2.6 nM), with 5hh (aryl = 3-ClPh, K-i = 900 pM) being 5-fold more potent than 2b. Conformationally restricted C2 side chains were examined, and many provided exceptionally potent inhibitors, of which 11j (ethylbiphenyl side chain) was established to be a 750 pM inhibitor. A systematic series of heteroatoms (O, NMe, S), electron-withdrawing groups (SO, SO2), and amides positioned within and hydroxyl substitutions on the linking side chain were investigated, which typically led to a loss in potency. The most tolerant positions provided effective inhibitors (12p, 6-position S, K-i = 3 nM, or 13d, 2-position OH, K-i = 8 nM) comparable in potency to 2b. Proteome-wide screening of selected inhibitors from the systematic series of > 100 candidates prepared revealed that they are selective for FAAH over all other mammalian serine proteases.

  DOI：

  10.1021/jm061414r

文献信息

• [EN] SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS<br/>[FR] DÉRIVÉS AMINOPROPIONIQUES SUBSTITUÉS COMME INHIBITEURS DE NÉPRILYSINE
  申请人：NOVARTIS AG

  公开号：WO2010136493A1

  公开（公告）日：2010-12-02

  The present invention provides a compound of formula I' or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, B1, X and n are defined herein. The invention also relates a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明提供了公式I'的化合物或其药学上可接受的盐，其中R1、R2、R3、R5、B1、X和n在此定义。本发明还涉及一种制造所述化合物的方法及其治疗用途。本发明进一步提供了药理活性剂的组合和药物组合物。
• [EN] CYCLIC PEPTIDE ANTIBIOTICS<br/>[FR] ANTIBIOTIQUES PEPTIDIQUES CYCLIQUES
  申请人：HOFFMANN LA ROCHE

  公开号：WO2019052545A1

  公开（公告）日：2019-03-21

  Provided herein are antibacterial compounds, wherein the compounds in some embodiments have broad spectrum bioactivity. In various embodiments, the compounds act by inhibition of lipoprotein signal peptidase II (LspA), a key protein in bacteria. Pharmaceutical compositions and methods for treatment using the compounds described herein are also provided.

  本文提供了抗菌化合物，其中在某些实施例中，这些化合物具有广谱生物活性。在各种实施例中，这些化合物通过抑制脂蛋白信号肽酶II（LspA）来发挥作用，这是细菌中的关键蛋白质。还提供了使用所述化合物的药物组合物和治疗方法。
• Diastereoselective palladium(0)-catalyzed reactions of lithium enolates of chiral N-acyloxazolidinones. Asymmetric synthesis of 2-substituted (E)-4-alkylidenepentanedioates
  作者：Hideyuki Kanno、Ken Osanai

  DOI：10.1016/0040-4039(95)01043-h

  日期：1995.7

  The palladium(0)-catalyzed reactions of lithium enolates 1 of N-acyloxazolidinones with 3-acetoxy-2-methylenealkanoates 2, easily prepared via DABCO-catalyzed coupling of corresponding aldehydes with acrylates, proceeded diastereoselectively and regioselectively to give chiral N-[(E)-4-alkoxycarbonyl-4-pentenoyl]oxazolidinones3, useful intermediates of metallopeptidase inhibitors.

  钯（0）烯醇化物锂催化的的反应1的Ñ与3-乙酰氧基-2- methylenealkanoates -acyloxazolidinones 2，通过容易地制备DABCO催化对应与丙烯酸酯的醛的联接，非对映选择性进行，并且区域选择性，得到手性ñ - [（E）-4-烷氧基羰基-4-戊烯基]恶唑烷酮3，金属肽酶抑制剂的有用中间体。
• Substituted aminopropionic derivatives as neprilysin inhibitors
  申请人：Coppola Gary Mark

  公开号：US08394853B2

  公开（公告）日：2013-03-12

  The present invention provides a compound of formula I′; or a pharmaceutically acceptable salt thereof, wherein R1, R2, R3, R5, B1, X and n are defined herein. The invention also relates a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明提供了I'式化合物；或其药学上可接受的盐，其中R1、R2、R3、R5、B1、X和n在此定义。本发明还涉及制备本发明化合物的方法及其治疗用途。本发明还提供了一种药理活性剂的组合物和制药组合物。
• SUBSTITUTED AMINOPROPIONIC DERIVATIVES AS NEPRILYSIN INHIBITORS
  申请人：COPPOLA Gary Mark

  公开号：US20140296240A1

  公开（公告）日：2014-10-02

  The present invention provides a compound of formula I′; or a pharmaceutically acceptable salt thereof, wherein R 1 , R 2 , R 3 , R 5 , B 1 , X and n are defined herein. The invention also relates a method for manufacturing the compounds of the invention, and its therapeutic uses. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.

  本发明提供了式I'的化合物；或其药学上可接受的盐，其中R1、R2、R3、R5、B1、X和n在此定义。本发明还涉及制造本发明化合物的方法及其治疗用途。本发明还提供了一种药理活性剂的组合和制药组合物。